A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AG-348 IN NOT REGULARLY TRANSFUSED ADULT SUBJECTS WITH PYRUVATE KINASE DEFICIENCY
- Registry ID
- AG348-C-006
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- AGIOS PHARMACEUTICALS INC
- Start date
- 2018-07-05
- Completion date
- 2021-04-14
- Last update
- 2018-05-17
Conditions
- PYRUVATE KINASE DEFICIENCY
Related clinical trials
- A ROLLOVER STUDY TO PROVIDE CONTINUED ACCESS TO MITAPIVAT FOR PARTICIPANTS WHO PREVIOUSLY COMPLETED AN AGIOS-SPONSORED MITAPIVAT STUDY
- A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MITAPIVAT IN PEDIATRIC SUBJECTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED, FOLLOWED BY A 5-YEAR OPEN-LABEL EXTENSION PERIOD
- A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MITAPIVAT IN PEDIATRIC SUBJECTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED, FOLLOWED BY A 5-YEAR OPEN-LABEL EXTENSION PERIOD
View on source registry